SGLT2 Inhibitors (heart failure)
High-yield Verified · Oct 2026The kidney normally reclaims almost all filtered glucose, mostly through SGLT2 in the proximal tubule. Blocking it turns the urine into a glucose and sodium outlet — which is why one mechanism treats diabetes, heart failure and chronic kidney disease, and why its harms are infections, volume loss and ketoacidosis with a near-normal glucose.
Nursing view → administration, monitoring and patient teaching
Drugs
Mechanism
Empagliflozin and dapagliflozin inhibit SGLT2, the transporter in the proximal tubule responsible for most reabsorption of filtered glucose, so they lower the renal threshold for glucose and increase urinary glucose excretion. They also reduce sodium reabsorption, increasing sodium delivery to the distal tubule.
How the kidney reclaims glucose
The kidneys filter about 180 g of glucose a day, and the proximal tubule normally reabsorbs nearly all of it. More than 90% is taken up by SGLT2, a low-affinity, high-capacity transporter; the later parts of the proximal tubule reclaim the rest through the high-affinity, low-capacity SGLT1. Both sit in the apical membrane and couple glucose to sodium, driven by the sodium gradient that the basolateral Na⁺/K⁺-ATPase creates; glucose then leaves the cell passively through GLUT2.
Reabsorption rises with plasma glucose until it reaches the tubule’s maximum — the renal threshold — beyond which glucose spills into the urine, as in uncontrolled diabetes. In type 2 diabetes there appears to be a maladaptive upregulation of SGLT2 that contributes to hyperglycemia. Nature’s own experiment makes the point: a mutation in SGLT2 causes familial renal glucosuria.
Glucosuria: lowering glucose through the urine
By competitively inhibiting SGLT2, these drugs reduce glucose reabsorption by about 30–60%, lower the renal threshold and increase urinary glucose excretion — about 64–78 g a day with empagliflozin and about 70 g a day with dapagliflozin — together with a rise in urine volume. Hypoglycemia arises mainly when the drug is combined with insulin or an insulin secretagogue such as a sulfonylurea.
Because the drug works on filtered glucose, glycemic efficacy depends on kidney function: dapagliflozin is not recommended for glycemic control below an eGFR of 45 and empagliflozin below 30 mL/min/1.73 m². The calories lost in the urine bring modest weight loss, and the natriuresis lowers blood pressure. After a dose is stopped, urinary glucose excretion takes about 3 days to return to baseline.
Natriuresis: why the heart and kidneys benefit
SGLT2 reabsorbs sodium along with glucose, so blocking it increases sodium delivery to the distal tubule. That increases tubuloglomerular feedback: the afferent arteriole constricts and intraglomerular pressure falls, which lowers albuminuria and slows chronic kidney disease. The labels describe the same downstream effects — increased tubuloglomerular feedback, reduced intraglomerular pressure, lower cardiac preload and afterload, and downregulation of sympathetic activity.
For the heart, natriuresis and diuresis reduce preload, arterial vasodilation reduces afterload, and the extra distal sodium delivery suppresses the renin–angiotensin–aldosterone system. A metabolic idea — the “thrifty substrate” hypothesis — adds that mild, persistent hyperketonemia supplies β-hydroxybutyrate as an efficient myocardial fuel. These benefits — fewer heart-failure hospitalizations, preserved renal function and lower cardiovascular mortality — apply in patients with or without diabetes.
The cost of a glucose outlet: ketones and infections
Euglycemic ketoacidosis follows from the hormone balance. Losing glucose in the urine lowers insulin while glucagon rises — SGLT2 inhibitors also directly stimulate glucagon release — and the higher glucagon/insulin ratio drives lipolysis, free fatty acids and ketone production. The drugs also increase renal ketone reabsorption. Because glucose keeps draining into the urine, the blood glucose stays deceptively near normal (< 250 mg/dL) despite a pH below 7.3 and bicarbonate below 18 mEq/L. Fasting, surgery, infection, reduced intake and lower insulin doses tip the balance.
Treatment follows the mechanism: the drug is stopped, fluids are given, and insulin with dextrose is continued until the acidosis resolves — insulin should not be withheld because the glucose looks normal. The glucose-rich urine also favours genitourinary infection, including Fournier’s gangrene, a rapidly progressive, polymicrobial necrotizing fasciitis of the perineum and genitals with a mortality near 40%, in which pain out of proportion to the findings is the classic early clue.
Comparing the drugs
Empagliflozin versus dapagliflozin
| Drug | Urinary glucose loss | Half-life | Metabolism | Excretion | Glycemic use not recommended below | Type 2 diabetes CV outcome on label |
|---|---|---|---|---|---|---|
| Empagliflozin | ~64–78 g/day | 12.4 h | Glucuronidation (UGT2B7, UGT1A3, UGT1A8, UGT1A9); no major metabolites | Urine 54%, feces 41% | eGFR 30 | Cardiovascular death (established CV disease) |
| Dapagliflozin | ~70 g/day | 12.9 h | UGT1A9 → inactive 3-O-glucuronide; CYP minor | Urine 75%, feces 21% (< 2% unchanged in urine) | eGFR 45 | Heart-failure hospitalization (CV disease or multiple risk factors) |
Both are labelled for heart failure (cardiovascular death and heart-failure hospitalization) and for chronic kidney disease at risk of progression, with or without diabetes.
Pharmacokinetics
- Absorption
- Peak at about 1.5 hours (empagliflozin) and within 2 hours (dapagliflozin, oral bioavailability 78%). Food lowers peak levels, but the effect is not clinically meaningful, so both may be taken with or without food.
- Distribution
- Protein binding about 86% (empagliflozin) and 91% (dapagliflozin); apparent volumes of about 74 L and 118 L indicate extensive tissue distribution.
- Metabolism
- Glucuronidation by UGT enzymes with minimal CYP involvement — UGT1A9 for dapagliflozin (to an inactive 3-O-glucuronide), UGT2B7, UGT1A3, UGT1A8 and UGT1A9 for empagliflozin. Empagliflozin neither inhibits nor induces CYP450 isoforms.
- Elimination
- Half-lives of about 12.4 hours (empagliflozin) and 12.9 hours (dapagliflozin) support once-daily dosing. Dapagliflozin and its metabolites leave mainly in urine (75%); empagliflozin’s drug-related material is split between urine (54%) and feces (41%).
- Site of action
- After glomerular filtration the drugs act at the luminal membrane of the early nephron, which is why reduced GFR blunts the glucose-lowering effect, while the dapagliflozin label lets treatment continue if the eGFR falls further.
- Offset
- Urinary glucose excretion approaches baseline about 3 days after the last dose, but ketoacidosis and glucosuria have lasted more than 6 days, and up to 2 weeks, after stopping an SGLT2 inhibitor.
Uses & drug choice
- Type 2 diabetes — with diet and exercise to improve glycemic control (adults and children 10 years and older)
- Heart failure, with or without diabetes — to reduce cardiovascular death and heart-failure hospitalization in adults
- Chronic kidney disease at risk of progression — to reduce sustained eGFR decline, end-stage kidney disease, cardiovascular death and hospitalization
- Empagliflozin for type 2 diabetes with established cardiovascular disease — to reduce cardiovascular death
- Dapagliflozin for type 2 diabetes with cardiovascular disease or multiple risk factors — to reduce heart-failure hospitalization
Adverse effects
- Genital mycotic infections and urinary tract infections
- The drugs raise urinary glucose excretion, and glucose-rich urine increases the risk of genitourinary infections in both men and women; a history of such infections raises the risk further.
- Ketoacidosis with a near-normal glucose
- Urinary glucose loss lowers insulin and the drugs stimulate glucagon; the higher glucagon/insulin ratio drives lipolysis and ketogenesis, renal ketone reabsorption rises, and ongoing glucosuria keeps the blood glucose below the usual DKA range.
- Fournier’s gangrene and serious genitourinary infection
- A polymicrobial aerobic and anaerobic infection spreading along fascial planes, causing vessel thrombosis and tissue necrosis; SGLT2 inhibitors, as glycosuric drugs, are listed among its associations, and diabetes itself is a major risk factor.
- Volume depletion, hypotension, acute kidney injury
- Osmotic diuresis from urinary glucose plus natriuresis contracts intravascular volume — most in older adults, patients with an eGFR below 60, or those on loop diuretics.
Interactions
Contraindications
- Hypersensitivity to the drug (e.g., angioedema, anaphylaxis) — Hypersensitivity is the contraindication on both labels; serious reactions, including angioedema and (with dapagliflozin) anaphylaxis, have been reported.
- Type 1 diabetes use caution — Not recommended for glycemic control in type 1 diabetes — SGLT2 inhibitors significantly increase the risk of diabetic ketoacidosis there.
High-yield
- Glucose out — glucosuria lowers blood glucose, with calorie loss
- Sodium out — natriuresis lowers preload and, via tubuloglomerular feedback, intraglomerular pressure (heart failure and CKD benefit)
- What goes out brings the harms: genital and urinary infections (including Fournier’s), volume depletion
- Euglycemic DKA on an SGLT2 inhibitor: glucose < 250 mg/dL but pH < 7.3 and bicarbonate < 18
- Check ketones whenever the patient looks unwell, whatever the glucose
- Stop the drug; treat with fluids and insulin plus dextrose
Practice questions
Q1A 58-year-old woman with type 2 diabetes taking metformin and empagliflozin has two days of nausea, vomiting and abdominal pain after a viral illness during which she ate little. She is tachypneic. Glucose is 190 mg/dL, pH 7.18, bicarbonate 11 mEq/L, and serum β-hydroxybutyrate is markedly elevated.
Which mechanism best explains the near-normal glucose?
- A.Metformin-induced suppression of hepatic gluconeogenesis causing lactic acidosis
- B.Insulin hypersecretion stimulated by empagliflozin
- C.Ongoing urinary glucose loss while a high glucagon/insulin ratio drives ketogenesis
- D.Impaired ketone production from inhibited lipolysis
- E.Renal tubular acidosis from SGLT1 blockade
Show answer
C. Ongoing urinary glucose loss while a high glucagon/insulin ratio drives ketogenesis — This is euglycemic diabetic ketoacidosis: glucose below 250 mg/dL with severe metabolic acidosis and ketonemia. Glucose keeps draining into the urine, insulin falls and glucagon rises (SGLT2 inhibitors also stimulate glucagon release), so lipolysis and ketogenesis run while blood glucose stays near normal; reduced intake and illness are typical triggers. The drug is stopped and the patient is treated with fluids and insulin plus dextrose. Metformin-associated lactic acidosis is not the explanation: ketones must be raised to make this diagnosis, and lactic acid may rise but should not account entirely for the anion gap.
Q2A 62-year-old man with heart failure with reduced ejection fraction and no diabetes is started on dapagliflozin. His glucose stays normal, yet his heart-failure symptoms improve.
Which effect most directly contributes to the benefit in a patient without diabetes?
- A.Increased insulin secretion
- B.Natriuresis that lowers preload, with reduced afterload and sympathetic activity
- C.Direct positive inotropy through β1 stimulation
- D.Blockade of the mineralocorticoid receptor
- E.Inhibition of hepatic gluconeogenesis
Show answer
B. Natriuresis that lowers preload, with reduced afterload and sympathetic activity — Dapagliflozin reduces sodium as well as glucose reabsorption, increasing distal sodium delivery; the labels link this to lower cardiac preload and afterload and downregulated sympathetic activity, and natriuresis and diuresis reduce preload. Its heart-failure indication — reducing cardiovascular death and heart-failure hospitalization — applies with or without diabetes. Dapagliflozin works by inhibiting SGLT2 in the proximal tubule — it is not an insulin secretagogue, a β1 agonist, a mineralocorticoid-receptor blocker or an inhibitor of gluconeogenesis — and its hypoglycemia risk arises mainly when it is combined with insulin or an insulin secretagogue.
Q3A 17-year-old has glucose in the urine on routine testing. Fasting glucose and HbA1c are normal; there is no aminoaciduria, phosphaturia or acidosis. A first-degree relative has the same finding.
A loss-of-function mutation in which transporter is most likely?
- A.SGLT2
- B.GLUT2
- C.SGLT1
- D.GLUT4
- E.Na⁺/K⁺-ATPase
Show answer
A. SGLT2 — Isolated glucosuria with normal plasma glucose points to familial renal glucosuria, caused by an SGLT2 mutation; SGLT2 performs more than 90% of proximal glucose reabsorption. An SGLT1 mutation causes glucose-galactose malabsorption, a GLUT2 mutation Fanconi-Bickel syndrome, and Fanconi syndrome adds phosphaturia, aminoaciduria and acidosis.
Q4A 66-year-old man with type 2 diabetes on dapagliflozin reports 24 hours of severe perineal and scrotal pain with fever. The skin shows only mild erythema, but he winces at light touch well beyond the visible area.
What is the most important next step?
- A.Oral fluconazole for presumed genital candidiasis
- B.Increase the dapagliflozin dose to improve glucose control
- C.Reassurance and follow-up in a week
- D.Stop dapagliflozin and arrange urgent surgical evaluation with broad-spectrum antibiotics
- E.Topical antibiotic cream
Show answer
D. Stop dapagliflozin and arrange urgent surgical evaluation with broad-spectrum antibiotics — Pain out of proportion to the findings in the perineum with fever suggests Fournier’s gangrene, a necrotizing fasciitis linked to SGLT2 inhibitors. The labels say to evaluate immediately and, if it is suspected, to discontinue the drug and institute prompt medical and surgical treatment; time to surgery is the most important factor in mortality, which is about 40%. Raising the dose, waiting a week or applying a topical antibiotic would each delay that evaluation, discontinuation and surgery.
Sources
- JARDIANCE (empagliflozin) — mechanism, pharmacokinetics, ketoacidosis, genitourinary infections (FDA label) — FDA / DailyMed
- FARXIGA (dapagliflozin) — mechanism, pharmacokinetics, indications, interactions (FDA label) — FDA / DailyMed
- Sodium-Glucose Transport 2 (SGLT2) Inhibitors — cardiorenal mechanisms, pharmacokinetics — StatPearls (NCBI)
- Physiology, Glycosuria — SGLT1/SGLT2/GLUT2, renal threshold, familial renal glucosuria — StatPearls (NCBI)
- Euglycemic Diabetic Ketoacidosis — glucagon/insulin ratio, diagnosis, treatment — StatPearls (NCBI)
- Fournier Gangrene — polymicrobial necrotizing fasciitis, SGLT2 association — StatPearls (NCBI)
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.